Industry
Biotechnology
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
March 28, 2024 | 11:37 am
Portfolio Pulse from Avi Kapoor
December 27, 2023 | 7:11 pm
Portfolio Pulse from Benzinga Newsdesk
December 27, 2023 | 2:29 pm
Portfolio Pulse from Avi Kapoor
December 27, 2023 | 1:14 pm
Portfolio Pulse from Benzinga Newsdesk
December 26, 2023 | 10:09 pm
Portfolio Pulse from Benzinga Insights
December 15, 2023 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
December 15, 2023 | 11:30 am
Portfolio Pulse from Benzinga Newsdesk
December 15, 2023 | 10:53 am
Portfolio Pulse from Benzinga Newsdesk
December 15, 2023 | 9:54 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.